Sepsis Research Analysis
Q1 2026 sepsis research converged on biology-informed triage, rapid bedside subphenotyping, and host-directed therapeutics. Pragmatic clinical implementation advanced with procalcitonin-guided ED workflows reducing 28-day mortality and a 1-hour IL-6/sTNFR1+bicarbonate panel enabling ARDS subphenotype assignment for precision enrollment. Parsimonious biomarker frameworks (cDIP) operationalized immune dysregulation and identified steroid-responsive patients, while multi-omic risk enrichment (BEYON
Summary
Q1 2026 sepsis research converged on biology-informed triage, rapid bedside subphenotyping, and host-directed therapeutics. Pragmatic clinical implementation advanced with procalcitonin-guided ED workflows reducing 28-day mortality and a 1-hour IL-6/sTNFR1+bicarbonate panel enabling ARDS subphenotype assignment for precision enrollment. Parsimonious biomarker frameworks (cDIP) operationalized immune dysregulation and identified steroid-responsive patients, while multi-omic risk enrichment (BEYOND) demonstrated the feasibility of biomarker-enriched adjunctive trials. Mechanistic studies mapped actionable host–pathogen and immunometabolic circuits (STAT1/PSMα3, ERβ–STOML2, EGFR–PGLYRP1–TREM-1) and a platelet-driven thrombo-inflammatory axis (PITT). A disease-tolerance/aging paradigm reframed outcome targets beyond pathogen eradication, aligning with cross-disciplinary strategies from stewardship to anti-virulence.
Selected Articles
1. A randomized controlled trial of precision bezlotoxumab treatment for Clostridioides difficile infection.
A two-stage program developed the BEYOND multi-omic risk score and randomized 44 high-risk CDI patients to bezlotoxumab plus standard care versus placebo, reducing a composite of organ dysfunction/relapse/death (31.8% vs 72.7%).
Impact: Demonstrates risk-enriched precision adjunctive therapy with clinically meaningful benefit, offering a practicable pathway for biomarker-guided anti-infective adjuncts.
Clinical Implications: If externally validated and operationalized, BEYOND-guided bezlotoxumab could selectively prevent organ dysfunction, relapse, and death in high-risk CDI; requires assay infrastructure and cost-effectiveness evaluation.
Key Findings
- BEYOND risk score (multi-omic) achieved sensitivity 84.6% and specificity 95.8% for unfavorable outcomes.
- In BEYOND-high patients, bezlotoxumab plus standard care reduced composite organ dysfunction/relapse/death to 31.8% vs 72.7% (p=0.015).
- Demonstrates feasibility of biomarker-enriched adjunctive therapy in infection care.
2. Quantifying immune dysregulation in pneumonia and sepsis with a parsimonious machine-learning model: a multicohort analysis across care settings and reanalysis of a hydrocortisone randomised controlled trial.
A three-biomarker ML framework (procalcitonin, sTREM-1, IL-6) reproduced an immune dysregulation continuum (DIP/cDIP) originally defined by 35 biomarkers, validated across multiple external cohorts. Post-hoc RCT reanalysis showed hydrocortisone reduced mortality only in severely dysregulated patients, enabling biomarker-stratified immunomodulation.
Impact: Provides a validated, pragmatic tool to operationalize immune status and target immunomodulators to likely responders.
Clinical Implications: Adopt PCT/sTREM-1/IL-6 scoring to stratify sepsis patients for corticosteroids and other immunomodulators, with prospective validation in sepsis-specific RCTs.
Key Findings
- Three-marker model predicted DIP stage with ~91% accuracy and generalized across five external cohorts.
- Higher cDIP associated with increased mortality and secondary infections.
- Hydrocortisone reduced 30-day mortality only in severe dysregulation (DIP3 or cDIP ≥0.63).
3. Platelet-derived integrin- and tetraspanin-enriched tethers exacerbate severe inflammation.
Mechanistic work identifies platelet-derived integrin- and tetraspanin-enriched tethers (PITTs) that form under flow, tether to leukocytes/endothelium, and amplify vascular inflammation; αIIbβ3 blockade mitigated immune-mediated tissue damage in infection/endotoxemia models, and human correlative data linked PITT formation with sepsis severity.
Impact: Reveals a previously unrecognized platelet structure linking thrombosis and inflammation, nominating the αIIbβ3/PITT axis as a translational target and potential severity biomarker in sepsis.
Clinical Implications: Supports trials of αIIbβ3/PITT-modulating strategies to reduce thrombo-inflammation; PITT quantification may aid risk stratification and monitoring, with careful bleeding-risk evaluation for integrin blockade.
Key Findings
- Flow-triggered αIIbβ3 ligation generates PITTs tethering to leukocytes and endothelium.
- PITTs amplify vascular inflammation; αIIbβ3 blockade reduces immune-mediated tissue damage in models.
- Human sepsis and severe COVID-19 cohorts show increased PITT formation and αIIbβ3 loss correlating with worse outcomes.
4. Disease tolerance and infection pathogenesis age-related tradeoffs in mice.
This study reframes infection outcomes through disease tolerance—limiting host damage without pathogen eradication—and demonstrates age-related tradeoffs shaping pathogenesis, motivating tissue-protective and tolerance-enhancing therapeutic strategies.
Impact: Provides a paradigm shift from pathogen elimination to host damage control, with broad translational implications for adjunctive therapy development and risk stratification in older patients.
Clinical Implications: Encourages trials of endothelial protection, metabolic reprogramming, and tolerance-enhancing interventions alongside antimicrobials, tailored to aging physiology.
Key Findings
- Disease tolerance is a distinct host-defense strategy limiting physiological damage.
- Age-related tradeoffs alter survival and organ injury patterns in infection models.
- Therapeutic prioritization should include tissue-protective/tolerance pathways.
5. EGFR orchestrates neutrophil activation and NETosis via CEBPβ-dependent PGLYRP1 induction.
Neutrophil-intrinsic EGFR signaling recruits MAPK14 to activate CEBPβ, inducing PGLYRP1 and amplifying TREM-1 signaling and pathological NETosis; neutrophil-specific EGFR deletion reduced cytokine storm, NETs, tissue injury, and mortality in polymicrobial sepsis models.
Impact: Defines a druggable neutrophil circuit from receptor activation to NETosis and mortality with integrated human–mouse evidence, prioritizing EGFR/PGLYRP1/TREM-1 as targets.
Clinical Implications: Supports development of EGFR-pathway modulators or downstream PGLYRP1/TREM-1 blockers and suggests neutrophil biomarkers for stratification in sepsis.
Key Findings
- Neutrophil EGFR expression is elevated in sepsis and correlates with severity.
- Neutrophil-specific EGFR deletion improves survival and reduces NET formation and tissue injury in vivo.
- Mechanism: EGFR → MAPK14 → CEBPβ → PGLYRP1 → autocrine TREM-1 amplification driving NETosis.
6. Effects of a comprehensive antibiotic stewardship program on antibiotic prescribing for acute respiratory infections in rural facilities: a cluster randomized trial.
A pragmatic cluster RCT across 34 rural township hospitals (97,239 consultations) found a multi-component, digitally enabled stewardship program cut antibiotic prescribing for acute respiratory infections from 71% to 26% without increasing 30-day hospitalizations for respiratory illness or sepsis.
Impact: Real-world, scalable stewardship reduced antibiotic use substantially without short-term harm, directly impacting AMR containment and sepsis prevention strategies.
Clinical Implications: Health systems can implement multi-component digital stewardship (EMR prompts, clinician training, peer review, patient education) to curb inappropriate antibiotics while monitoring resistance trends.
Key Findings
- Antibiotic prescribing for ARIs fell from 71% to 26% (adjusted risk difference −39 pp; P<0.001).
- No increase in 30-day hospitalization for respiratory illness or sepsis.
- Feasible across 34 rural hospitals over 12 months with EMR prompts, training, peer review, and patient education.
7. Targeting phenol-soluble modulin α3-driven M1 macrophage polarization and necroptosis mitigates MRSA infection in mice.
Mechanistic work shows MRSA virulence factor PSMα3 drives M1 macrophage polarization and necroptosis via an ISGF3–necrosome axis downstream of FPR2. Pharmacologic STAT1 inhibition with the approved drug fludarabine reduced MRSA burden and improved outcomes in murine sepsis and pneumonia models, supporting host-directed anti-virulence strategies.
Impact: Identifies a targetable host–pathogen signaling axis and demonstrates efficacy with a repurposed, clinically available drug in sepsis-relevant models, accelerating translational prospects.
Clinical Implications: Supports adjunctive anti-virulence therapy development for MRSA sepsis; next steps include defining safety, dosing, and patient-selection biomarkers (e.g., PSMα3 activity) prior to human trials.
Key Findings
- PSMα3 triggers M1 polarization and necroptosis via ISGF3–necrosome interactions.
- FPR2 mediates PSMα3 effects; STAT1 is a central downstream node.
- Fludarabine (STAT1 inhibitor) reduced MRSA burden and improved survival in murine sepsis/pneumonia.
8. Procalcitonin testing combined with NEWS2 evaluation compared with usual care based on NEWS2 for identification of sepsis and antibiotic initiation in the emergency department in England and Wales (PRONTO): a multicentre, randomised, controlled, open-label, phase 3 trial.
A pragmatic multicentre phase 3 RCT (n=7,667) found that adding rapid procalcitonin testing to NEWS2 did not alter 3‑hour IV antibiotic initiation but reduced 28‑day mortality (13.6% vs 16.6%). Procalcitonin influenced clinician decision-making in ~65% of cases, indicating mortality benefit from biomarker-guided triage independent of immediate antibiotic timing.
Impact: Delivers high-quality evidence that a biomarker-guided ED workflow can reduce mortality, informing immediate implementation and stewardship strategies.
Clinical Implications: Consider implementing near-patient procalcitonin alongside NEWS2 with evaluation of adherence, antibiotic duration, and de-escalation; integrate into ED triage pathways with ongoing outcomes monitoring.
Key Findings
- No difference in 3-hour IV antibiotic initiation (48.4% vs 48.2%).
- Lower 28-day mortality with PCT-guided care (13.6% vs 16.6%; adjusted risk difference −3.12%).
- PCT altered clinical decisions in ~64.7% of cases; adverse events similar across groups.
9. Estrogen receptor β deficiency increases susceptibility to sepsis through metabolic reprogramming-induced macrophage pyroptosis.
Reduced ERβ expression in sepsis patients was linked mechanistically to fatty-acid-oxidation–driven acetyl-CoA accumulation and Stoml2 K221 acetylation, causing mitochondrial dysfunction and macrophage pyroptosis. Mutating Stoml2 K221 rescued mitochondrial function and improved survival in septic mice, nominating a druggable host-susceptibility axis.
Impact: Defines a concrete ERβ–immunometabolism–pyroptosis pathway with in vivo rescue, yielding biomarker and therapeutic leads for personalized sepsis care.
Clinical Implications: Evaluate ERβ as a susceptibility/prognostic marker and advance selective ERβ modulators or FAO/acetylation pathway inhibitors to prevent macrophage pyroptosis in high-risk patients.
Key Findings
- ERβ expression is reduced in sepsis and inversely correlates with severity.
- ERβ deficiency increases FAO and acetyl-CoA, acetylating Stoml2 K221, triggering mitochondrial dysfunction and pyroptosis.
- Stoml2 K221 mutation mitigates pyroptosis and improves survival in septic mice.
10. Bedside identification of subphenotypes in acute respiratory failure (PHIND): a multicentre, observational cohort study.
A prospective multicentre cohort (n=512) implemented a 1-hour near-patient assay (IL-6, sTNFR1) plus bicarbonate to classify ARDS/AHRF into hyper- vs hypoinflammatory subphenotypes with marked prognostic separation (60-day mortality 51% vs 28%). The study operationalizes rapid bedside subphenotyping suitable for precision enrollment.
Impact: First prospective demonstration that a 1-hour bedside panel can reproducibly stratify ARDS subphenotypes with large prognostic separation, enabling precision critical care.
Clinical Implications: ICUs can implement near-patient IL-6/sTNFR1 + bicarbonate to guide targeted therapies and trial enrollment; immediate operational planning and platform access are key.
Key Findings
- Near-patient IL-6/sTNFR1 with bicarbonate classified hyper- vs hypoinflammatory phenotypes within ~1 hour.
- Hyperinflammatory ARDS had markedly higher 60-day mortality (51% vs 28%; adjusted OR 2.7).
- Feasibility across 30 centers supports bedside precision stratification.